Liste des publications

Toutes les publications des équipes du C3M.

Exporter en CSV
Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Auteurs Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N

Molecular cancer therapeutics Fév 2019

Editorial: Metformin: Beyond Diabetes.

Auteurs Bost F, Rena G, Viollet B

Frontiers in endocrinology Jan 2019

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

Auteurs Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Schneider D, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W

Frontiers in immunology Jan 2019

Hypoxia protects against the cell death triggered by oxovanadium-galactomannan complexes in HepG2 cells.

Auteurs Meyenberg Cunha-de Padua M, Noleto GR, de Oliveira Petkowicz CL, Cadena SMSC, Bost F, Pouysségur J, Mazure NM

Cellular & molecular biology letters Jan 2019

The metabolic modulator PGC-1α in cancer.

Auteurs Bost F, Kaminski L

American journal of cancer research Jan 2019

Regulation of tumor-stroma interactions by the unfolded protein response.

Auteurs Obacz J, Avril T, Rubio-Patiño C, Bossowski JP, Igbaria A, Ricci JE, Chevet E

The FEBS journal Jan 2019

Natural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease.

Auteurs Luci C, Vieira E, Perchet T, Gual P, Golub R

Frontiers in immunology Jan 2019

Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.

Auteurs Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E

Frontiers in immunology Jan 2019

Subcellular Heterogeneity of the microRNA Machinery.

Auteurs Trabucchi M, Mategot R

Trends in genetics : TIG Jan 2019

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.

Auteurs Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G

Theranostics Jan 2019